The obesity drug race is heating up in more ways than one.Eli Lilly, the world’s biggest pharmaceutical company by market value, benefited from some good news Friday.The Food and Drug Administration approved Lilly’s blockbuster drug for weight-loss Zepbound to also treat sleep apnea,

Shares in Ozempic maker Novo Nordisk crashed, after an experimental anti-obesity shot fell short of expectations. The shares recently stood about 23% lower in Copenhagen. That put the stock on course for its lowest close since August 2023.

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late-stage clinical trial findings reported Friday.